Female sexual dysfunction affects an estimated 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. The condition can affect a woman's desire, ability to become aroused and orgasm and may include sexual pain. Despite the high prevalence, FSD is poorly understood and there are no currently approved drug treatments.
Scope
Summary of prevalence estimates of FSD in the seven major markets (US, Japan, France Germany, Italy, Spain and the UK)
Extensive primary research with key opinion leaders in women's health and FSD on current treatment and future directions
Secondary research including IMS MIDAS and R&D Focus databases, IDdb3 and Dolphin patent database
Report Highlights Patient potential in FSD is high but with no approved drug treatment there is considerable unmet need in the market. Datamonitor believes that there is the potential to develop a parallel market to that of male erectile dysfunction, which is now a multi-billion dollar arena.
Success of drugs for FSD will depend on physician and patient education and overcoming difficulties in patient presentation and diagnosis. There will be a need for significant investment in promotional activity before and during launch campaigns in order to reach full commercial potential.
The FDA rejection of Procter & Gamble's Intrinsa application for female sexual desire disorder a major setback in developing the market. Many smaller pipeline players are unlikely to be able to invest in the necessary awareness campaigns at launch of their products and could represent licensing and marketing opportunities.
Reasons to Purchase
Assess current disease definitions, classifications and etiology and identify difficulties in accessing the patient population
Examine approaches to FSD treatment in the pipeline and gauge the impact of P&G's Intrinsa (testosterone patch) NDA withdrawal on the market
Identify alternative approaches to FSD treatment and highlight opportunities for developing the market
Table of Contents
ABOUT DATAMONITOR - page 2
OVERVIEW - page 4
This product has been designed for delivery in a slide pack format (ppt). - page 4
Please select the slide pack option from the download menu at the side of the page - page 4
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.
